Remus Pharmaceuticals share price
NSE: REMUSPharmaceuticals & Biotechnology
Last close ₹880.60down ₹20.60 (2.29%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹901.20.
52-week range of traded prices to 23 Oct 2026
₹580.00Low, 9 Mar 2026₹1,039.00High, 15 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹1,038 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 20 May 2026
- 28.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 20 May 2026
- 3.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 20 May 2026
- 12.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 20 May 2026
- 13.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 20 May 2026
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day.
- 2,800
Results
Consolidated; ₹ crore, the charts by years to March, the table by half year.Half-yearly results
Half year to Mar 2026, against the half year beforeFiled 20 May
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹453 Crup 13.30%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹25 Crup 13.85%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 5.4%
Revenue by year
Peak revenue ₹854 Cr, year to Mar 2026
Net profit by year, a loss in red
| ₹ crore | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025Filed 19 May | Sep 2025Filed 10 Nov | Mar 2026Filed 20 May |
|---|---|---|---|---|---|---|
| Revenue | 29 | 183 | 273 | 348 | 400 | 453 |
| Net profit | 6 | 16 | 14 | 21 | 22 | 25 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 19.4% | 8.7% | 5.1% | 5.9% | 5.4% | 5.4% |
Consolidated. The 6 half years from Sep 2023, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMACEUTICALS, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 81% of 232 trading days over the last year.
LowestHighest
Its median24.6Industry median28.3
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 77% of 243 trading days over the last year.
LowestHighest
Its median2.7Industry median2.8
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.18.5
At or below today's level on 80% of 243 trading days over the last year.
LowestHighest
Its median16.3Industry median18.7
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 69% of 739 trading days over the last 3 years.
LowestHighest
Its median0.10%Industry median0.53%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −43.8% | +27.2% | −55.9% | 0.2% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 year is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Remus Pharmaceuticals in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 KopranKOPRAN | 1,190 | 47.6 | 2.2 | 21.8 | +12.0% | −28.4% | 4.8% | 6.2% | 1.22% |
 Bharat ParenteralsBPLPHARMA | 1,165 | – | 3.6 | 122.9 | −11.2% | – | – | −5.2% | 0.06% |
 Bajaj HealthcareBAJAJHCARE | 1,052 | 51.0 | 1.9 | 11.5 | +14.2% | −55.0% | 4.0% | 10.2% | 0.48% |
 Bafna PharmaceuticalsBAFNAPH | 1,048 | 134.6 | 10.9 | 92.1 | −3.1% | −5.8% | 8.6% | 4.0% | 0.00% |
 Lincoln PharmaceuticalsLINCOLN | 1,027 | 10.6 | 1.4 | 9.9 | +10.2% | +11.7% | 13.5% | 11.3% | 0.35% |
 Sigachi IndustriesSIGACHI | 959 | 37.8 | 1.8 | 23.2 | −9.6% | – | 4.5% | 4.3% | 0.40% |
 Aptus PharmaAPPL | 843 | 106.0 | 29.7 | – | – | – | 31.7% | – | 0.00% |
 Themis MedicareTHEMISMED | 836 | 20.9 | 2.1 | – | −12.8% | – | 10.0% | −10.5% | 0.55% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.Highest ₹1.00 a share, years to Mar 2025 and Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 22 Sep 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.50 |
| 14 Nov 2025 | Interim | ₹0.50 |
| 18 Sep 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.50 |
| 19 Nov 2024 | Interim | ₹1.00 |
| 2 May 2024 | Interim | ₹4.00 |
| 27 Oct 2023 | Interim | ₹2.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
7 Sep · Corporate action
5 Sep · Meeting
Remus Pharmaceuticals share price by year
Each calendar year to 2025.Remus Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 702.20 | −43.8% | 1,256.75 | 628.70 |
| 2024 | 1,248.75 | +30.5% | 1,362.28 | 610.74 |
| 2023 | 956.69 | – | 956.69 | 224.60 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2023 is from its first session, 29 May 2023.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 881.00 | 890.00 | 860.00 | 880.60 | 874.39 | 2,800 | – |
| 22 Oct 2026 | 911.00 | 935.00 | 897.00 | 901.20 | 912.75 | 3,100 | 87.1% |
| 21 Oct 2026 | 953.05 | 974.95 | 906.00 | 915.75 | 933.22 | 6,500 | 76.9% |
| 19 Oct 2026 | 1,000.00 | 1,000.00 | 972.90 | 984.50 | 985.74 | 3,400 | 64.7% |
| 16 Oct 2026 | 1,006.00 | 1,016.00 | 1,000.00 | 1,002.00 | 1,004.36 | 3,700 | 75.7% |
| 15 Oct 2026 | 1,014.00 | 1,039.00 | 990.00 | 1,011.55 | 1,021.43 | 13,100 | 55.0% |
| 14 Oct 2026 | 931.00 | 1,032.25 | 931.00 | 1,020.75 | 1,006.69 | 34,600 | 71.7% |
| 13 Oct 2026 | 928.00 | 932.90 | 919.90 | 925.00 | 927.56 | 1,700 | 76.5% |
| 12 Oct 2026 | 981.25 | 981.25 | 925.15 | 932.10 | 947.19 | 3,900 | – |
| 9 Oct 2026 | 975.00 | 1,009.95 | 957.25 | 976.35 | 982.69 | 10,600 | 71.7% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 4 Jul 2025 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 6 Jun 2024 | Bonus | 0.2500 | Holders received 3 bonus shares for every 1 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- Legal name
- Remus Pharmaceuticals Limited
- NSE symbol
- REMUS
- ISIN
- INE0O5T01011
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- May 2023
- Face value
- ₹10